

### Contents

#### In Perspective

A variety of indicators point to renewed strength ahead **1-2**

#### Spotlight Stock

This generic drug maker has great growth potential **1, 3**

**Growth Stocks 4-6**

**Oil and Gas Stocks 7**

**Value Stocks 8-9**

**Options 9**

**ETFs and Mutual Funds 10**

**Follow-Ups 11**

**In This Issue 12**

Log in to

[www.dickdavis.com](http://www.dickdavis.com)

Username: ddd673

Password: 62c99

### IN PERSPECTIVE

#### Was That A Bottom?

*Signs of a market bottom come in all shapes and sizes, from technical chart signals to a preponderance of terrible news on TV (a sign of pessimism and a bullish signal for contrary investors). Last week these indicators suddenly seemed to gain a critical mass. Below, our esteemed contributors weigh in on a couple positive signs.*

“Hadn’t quite figured out why stocks rallied sharply last week until the latest edition of Bloomberg Businessweek landed on my desk. ‘Grrrrr!,’ shouted the cover as a picture of a menacing bear with the caption, ‘What we can learn from the endless pessimism of Wall Street’s biggest bears,’ provided a magazine-cover contrarian buy signal. While not quite as ‘loud’ as the July 29, 2002 (right at the market bottom) ‘Angry Market’ Business Week cover that featured an equally threatening bear, history has shown that by the time the nation’s news magazines and business publications see fit to dedicate their best real estate to big moves in the stock market or the economy, the trend has often played out. Works in both directions, of course, as the patriotic Newsweek cover: ‘America’s Back! The Remarkable Tale of our Economic Turnaround,’ carried an April 19, 2010 date, very close to the peak of the market (and economic optimism) thus far this year.”

John Buckingham, The Prudent Speculator, [www.prudent-speculator.com](http://www.prudent-speculator.com), 877-817-4394, 6/14/10


(Continued on page 2)

### SPOTLIGHT STOCK: Dr. Reddy’s Laboratories, Ltd. (RDY)

*Cabot China & Emerging Markets Report is ranked the number-one performing newsletter over the last five years by Hulbert Financial Digest.*

“From the point of view of a pharmaceutical company, modern drugs are expensive to develop. From time- and labor-intensive development through expensive clinical trials and on to the dicey business of promoting and marketing a new drug, costs can be overwhelming. And the worst thing is that a company gets to enjoy only 20 years of patent protection for a new drug (although there are lots of tricks to stay ahead of the race in holding onto important drugs). But from the point of view of the consumer, modern drugs are just expensive, period. And the best thing is that after just 20 years (see note below), a drug can be duplicated by generic

(Continued on page 3)



**New Highs and Lows**

“There were 43 stocks on the new 52-week highs list on Friday compared with only 13 new lows. Thursday’s new lows were also less than 40, which is the dividing line between an internally weak versus strengthening market. The market is still chopping around trying to establish a base of support above the 60-week moving average but the good news is that we finally have a confirmed immediate-term bottom from both the SPX and the NYA. There are also some additional indications that next week could see some immediate-term buy signals popping up. The S&P 500 along with the NYSE Composite Index confirmed an immediate-term bottom Friday by closing two days higher above their respective 15-day moving averages. The 15-day MA is used by us to determine the relationship of the market to the dominant immediate-term trend, with a 2-day higher close following a corrective decline used to signal bottoms. This signal has a statistically high rate of marking the bottom, although we still need to see the market follow this up on Monday in order to get an immediate-term buy.”

Clif Droke, Momentum Strategies Report, [www.clifdroke.com](http://www.clifdroke.com), 6/11/10

**Put–Call Ratios**

“We’ve had quite a pullback since late April, but this week I have an indicator that makes a strong case that the bottom may be here, or at least near. Looking at the SPDR S&P 500 (SPY), a heavily traded exchange-traded fund (ETF) that follows the S&P 500 Index, puts are more expensive relative to calls now than they were even during the 2008 market crash. This may be the capitulation we’ve been looking for that indicates a market bottom.”

Rocky White, Schaeffer’s Monday Morning Outlook, [www.schaeffersresearch.com](http://www.schaeffersresearch.com), 800-448-2080, 6/12/10

**Buying and Selling Climaxes**

“Last week saw only 6 buying climaxes [but] 170 selling climaxes. ... Buying climaxes take place when a stock makes a 12-month high, but closes the week with a loss. They are a sign of distribution and indicate that stocks are moving from strong hands to weak ones. Selling climaxes occur when a stock makes a new 12-month low,

but then closes the week with a gain. They are a sign of accumulation and indicate that stocks are passing from weak hands to strong ones. Our work shows that sellers into buying climaxes and buyers into selling climaxes are right about 80% of the time after 4-6 months.”

Michael Burke & John Gray, Investors Intelligence, [www.investorsintelligence.com](http://www.investorsintelligence.com), 914-632-0422, 6/14/10


“Now that the sellers have pretty much done their thing, stocks finally got a chance to start returning to valuations that are based on earnings rather than fear. While there is a possibility that more negative surprises will come out of Europe, odds are the worst of this correction is already behind us.”

Jack Bowers, Fidelity Monitor, [www.fidelitymonitor.com](http://www.fidelitymonitor.com), 800-397-3094, 6/11/10

**Support Levels**

“The horizontal line in the chart [below] of the S&P 500 SPDR (SPY) shows that the \$105/share area has been revisited several times in the past five weeks and has always served as a floor to stock market prices, most recently on June 7. That does not mean that stocks are guaranteed to stay above this level. However, until (if) our indicators get more bearish, I expect \$105 on the S&P 500 SPDR to remain a floor that limits further downside risk (corresponding to about 1050 on the S&P 500 Index).”

Dr. Marvin Appel & Gerald Appel, Systems & Forecasts, [www.systemsandforecasts.com](http://www.systemsandforecasts.com), 800-829-6229, 6/9/10



<p><b>Dick Davis Digest</b> P.O. Box 2049 Salem, MA 01970 <b>Chloe Lutts, Editor</b></p>	<p><b>Contact us:</b> editorial@dickdavis.com or 978-745-5532</p> <p><b>Subscriptions:</b> subs@dickdavis.com</p>	<p><b>We appreciate your feedback: email us at <a href="mailto:comments@dickdavis.com">comments@dickdavis.com</a> or complete our brief survey at <a href="http://www.surveymonkey.com/dddsurvey">www.surveymonkey.com/dddsurvey</a></b></p> <p>Dick Davis Digest is published 24 times a year. Issue 674 will be published on July 7, 2010.</p>
--	---	--

drug manufacturers and sold to those who need it for far less money.

“That’s where **Dr. Reddy’s Laboratories, Ltd.** (RDY 31.08 NYSE) comes in. Dr. Reddy’s is a growing global power in the pharmaceutical business, with a lineup of more than 50 products offered in the U.S., more than 160 products marketed in Europe, and more than 200 branded formulations available in India, Russia and other emerging markets. Founded in 1984 by Dr. Anji Reddy (his Ph.D. is in Chemical Engineering), Dr. Reddy’s Labs is the main reason India has gone from a net drug importer to a net drug exporter. And as the company grows—both via its aggressive program of acquisition and by organic growth—it is ramping up its original pharmacological research in pursuit of original drugs.

“Dr. Reddy’s Labs is a global concern, with just 17% of revenue coming from India. North America contributes 35%, Western Europe 26% and Russia/Eastern Europe 11%. In terms of product mix, revenues are heavily weighted toward generic drugs (72% of 2009 revenues), with pharmaceutical services and active pharmaceutical ingredients (27%) and proprietary products (1%) making up the rest. The company launched more than 90 new generic products worldwide in the nine months ending March 31, and has 62 ANDAs (abbreviated new drug applications) in its generic pipeline.

“Note: Drug patents in the U.S. provide for 20 years of patent protection, but that period is measured from the date of the original application. Given the number of years needed to successfully complete clinical trials and receive FDA approval for distribution, the effective period of protection is usually between seven and 12 years. Since India agreed in 2005 to recognize international drug patents, there will be some lag in Dr. Reddy’s access to drugs patented after 2005, but that’s one reason the company is aggressively pursuing other business lines.

“Dr. Reddy’s bought a custom pharmaceuticals

services business from Roche in 2005 and took over Germany’s Betapharm in 2006. Transfer of Betapharm’s manufacturing division from Germany to India is expected to yield significant cost savings. Dr. Reddy’s original drug research centers on metabolic disorders, cardiovascular diseases and bacterial infection.

“The company’s earnings line is a little rocky, with Q1 2009 showing a large per-share loss due to an impairment charge following decreases in German pharmaceutical prices. But recent quarters have been terrific, and the future looks even brighter, with estimates of fiscal 2011 earnings up 219%.

“The chart for RDY is very strong, soaring from a March 2009 low of 7 to over 31 in recent trading. The stock’s 2010 history features a great run from a low of 23 following the January correction to 29 in early April. Then comes two months of total junk—high volatility and big swings that dropped the stock to an intraday low of 24 during the flash crash. In general though, the stock found support at 26 through April and May, which set the stage for a breakout run in late May and early June on slightly elevated volume. Clearly, there’s an institutional move in RDY’s direction going on, as institutional sponsorship is up from just 5 two quarters ago to 12 now.

“With the Cabot China-Timer still negative, it’s just not prudent to be doing much buying, if any at all. But if you have a large amount of cash and have purged your portfolio of losers, we think you can buy a small amount of RDY. This dividend-paying stock has a lot going for it, including the power to make progress while most of the rest of the China and emerging markets universe is stuck in the mud. BUY A LITTLE.”

Paul Goodwin, Cabot China & Emerging Markets Report, [www.cabot.net](http://www.cabot.net), 978-745-5532, 6/10/10

*For another leader in the booming generic drug market, see page 6.*

### Company Information

**Dr. Reddy’s Laboratories, Ltd.** (NYSE: RDY)

Hyderabad, India

**Web site:** <http://www.drreddys.com>

**52-week low/high:** \$14.03/\$33.14

**Shares Outstanding:** 168.67 million

**Institutionally Owned:** 12%

**Market Capitalization:** \$5.23 million

**Why Dr. Reddy’s:**

- Leadership Position in a Growth Industry
- Established Global Markets
- Growing Organically and Through Acquisitions
- Technically Strong

“With all the new environmental regulations, higher gas prices, and more ground shipments across the U.S., we’re seeing an excellent opportunity with **Cummins, Inc.** (CMI 75.25 NYSE). Cummins manufactures diesel and natural gas powered engines. But they also build electric power generation systems. The company is growing rapidly, including recent expansion in Dubai in the Middle East. The company has embraced the environmental movement and is profiting as a result. It’s also protected from new regulations on medium-and heavy-duty vehicles, as it’s years ahead of the government on possible changes to the law. The company has held up well through the recession and is poised for further growth once economic (not just the market) recovery takes hold. Technically, the stock just gave a major buy signal. After dropping down twice in May, the stock has a double bottom on the correction. And it recently moved back above the 50-day moving average, which is well above the 200-day moving average. It also has a much stronger double bottom in place from last spring, which gave it the foundation needed for a long rally. The trend for Cummins is definitely up. We’re buying high with plans to sell much higher. We’re initiating an immediate buy recommendation on CMI. It will carry a risk rating of 3 and a long-term strategy. It’s a buy up to \$75 and we have a target price of \$85.”

Richard Schmidt, Stellar Stock Alert, [www.stellarstockalert.com](http://www.stellarstockalert.com), 800-456-5705, 6/10

“**interCLICK, Inc.** (ICLK 3.92 Nasdaq) operates an online display advertising network that combines complete data and inventory transparency with specialized and specific targeting solutions. Powered by a proprietary data-enrichment technology platform, the Open Segment Manager system (OSM), interCLICK develops coherent data strategies for its advertising agency clients. These strategies allow the company’s clients to optimize online advertising campaign performance and connect to targeted audiences more effectively. interCLICK generates its revenue through the sale of online display advertising, which is placed on third party publisher websites. In the company’s latest reported first quarter, sales increased approximately 69% to \$14.2 million from \$8.4 million in the first quarter of last year. interCLICK reported an operating loss in the latest reported first quarter. The company increased operating expenses in the quarter to invest in the business, and we expect those investments to yield growth rates in line with our typical expectations later this year. ... These shares may be appropriate for risk-oriented investors.”

Jim Oberweis, The Oberweis Report, [www.oberweisreport.com](http://www.oberweisreport.com), 800-323-6166, 6/10

“We are reiterating our BUY rating and \$34 target price on Focus List selection **Starbucks Corp.** (SBUX 27.87 Nasdaq). The company has made efforts to restore earnings by slowing unit expansion, managing expenses, and implementing programs to increase traffic. Customer traffic improved during the second quarter of FY10 and the company’s return to positive same-store sales should continue. We expect investors to bid up the stock as earnings recover. Starbucks benefits from unprecedented brand loyalty as well as from economies of scale. We expect the company’s international expansion to accelerate in markets where initial results have been promising. In particular, Starbucks has received a positive response to its stores in China, and is now focusing on small- to mid-sized Chinese cities. Management believes that it must increase its store count in China before competitors enter the market. Our long-term rating remains BUY.”

Martha Freitag, Argus Weekly Staff Report, [www.argusresearch.com](http://www.argusresearch.com), 212-425-7500, 6/14/10

“**Activision Blizzard, Inc.** (ATVI 11.31 Nasdaq) is one of the largest developers of video games for video game systems, PCs and handheld devices in the world. Its games and brands include Call of Duty, Guitar Hero, Spider-Man, Shrek, James Bond, World of Warcraft, Tony Hawk, Starcraft and Cataclism. The games have a large following of loyal users, and are ideally suited for bringing out sequels that will resonate well with those users. ... The company also has a healthy pipeline of new game products, and licenses products from independent studios. ATVI proved to be recession-proof, in part because of its active acquisition efforts, having acquired Freestyle Games Inc., and Budcat Creations in 2008. The company has a strong balance sheet with \$3.3 billion in cash and no long-term debt. That financial strength will support more acquisitions going forward, as well as the stock repurchase program (authorized by the board of directors to buy back up to \$1 billion of the common stock).

“The recent pullback in the stock seems to be providing a buying opportunity. Morningstar has a fair value estimate of \$14 on the stock. First Call/Thomson Financial reports that of 35 Wall Street analysts that follow the stock, 18 rate it a strong buy, 15 rate it buy, and 2 rate it hold. None rate it as underperform or sell. We have an upside target of 13.25, and suggest a mental trailing protective stop initially set at 8.95. The risk is that Activision operates in a highly competitive industry in which popular games can fall out of favor, while success has attracted imitators and new start-ups.”

Sy Harding, Long and Short Stock Advisor, [www.longandshortstockadvisor.com](http://www.longandshortstockadvisor.com), 386-943-8014, 6/9/10

“**Express Scripts, Inc.** (ESRX 53.26 Nasdaq) is a pharmacy benefit manager (PBM). This type of company negotiates discounts on bulk generic prescription drugs and processes employer and insurance health plans. They also distribute drugs through the mail and provide consultation services for patients. In essence, they make purchasing prescription drugs cheaper and easier. ESRX’s business model appears to be working. In April of this year, Express Scripts surpassed Emerson Electric (NYSE: EMR) as the largest company in St. Louis, based on revenue. Express Scripts is also the second largest pharmacy benefits manager in the United States, behind Medco Health Solutions (NYSE: MHS). The December 2009 acquisition of NextRx, previously a division of WellPoint (NYSE: WLP), is helping to drive growth. ... Express Scripts could grow even more. If you’ve read recent health-care news, you may know that Walgreen (NYSE: WAG) and CVS Caremark (NSYE: CVS) are in a battle over honoring patients’ drug benefit plans. If the two companies don’t quickly resolve their differences, analysts believe Express Scripts could come onto the scene and scoop up some of CVS’ drug plans. This move could generate as much as \$1.3 billion in new business for Express Scripts. In early June of this year, Express Scripts opened a new \$60 million pharmacy automation center, adding 300 new jobs to its payroll. Reflective of this expansion, ESRX announced a 2 for 1 stock split, effective June 8th. Technically, ESRX is on a roll. Since hitting a low of \$21.38 in March 2009, the stock has surged more than 135%. In mid-May of this year, ESRX hit a record high of \$53.15. Despite recent market weakness, ESRX continues to hover near this level. The technicals suggest it could go yet higher. ESRX remains in a long-term bullish ascending triangle that has been forming for more than three months since March 2010. The major uptrend line of the triangle began in March 2009. The top of the triangle is resistance, near \$53.15. The height of the triangle is roughly \$5.15 from \$48 to \$53.15. If ESRX can break resistance, it will complete the ascending triangle pattern. The measuring principle—calculated by adding the height of the pattern to the break out level—projects the stock could then reach a minimum target of more than \$58 (\$5.15+ \$53.15). The intersection of the upper channel level gives a much higher target near \$70. ... These solid fundamentals, combined with the company’s strong technicals, make ESRX an attractive stock. However, I will wait to enter a position until ESRX has broken through key resistance, near \$53. My buy on stop order is at \$53.21. My target is \$63.95, ... the stop-loss is \$47.89, a support level which has held through the recent correction, except the day of the ‘Flash crash.’ The risk reward ratio is 1.98:1.”

Dr. Melvin Pasternak, Double-Digit Trading, [www.streetauthority.com](http://www.streetauthority.com), 301-216-2005, 6/13/10

“**Janus Capital Group, Inc.** (JNS 10.44 NYSE)—The asset management firm is being pressured due to exposure to declining retail stock markets and possible margin pressures. Heavy volume on the sell-off mode since the latter part of April has continued to date. Exiting apparent. Subject to further sell-off on any rebounds. Take Short Position: 9-11, Cover Short: 4, Stop Loss: 12.”

Joseph Parnes, Shortex Market Letter, [www.shortex.com](http://www.shortex.com), 800-877-6555, 6/9/10

*T-3 Energy Services provides equipment and services used to drill and maintain onshore and offshore oil and gas wells.*

“**T-3 Energy Services, Inc.** (TTES 31.98 Nasdaq) made its bear market lows at \$8.50 in December ’08 and \$9 in March ’09. It then moved to a bull market high of \$30 in April ’10 with a buying climax. The shares corrected to \$23. A bear trap reversal up followed that sell signal and trading then moved up to an upside breakout at \$30 on Friday, with follow through to \$32. It can be bought on a pullback to \$29 with a stop loss at \$25.”

Michael Burke & John Gray, Investors Intelligence, [www.investorsintelligence.com](http://www.investorsintelligence.com), 914-632-0422, 6/14/10

“**Ely Gold & Minerals, Inc.** (ELY.V 0.24 Toronto-V) is a new junior company looking to fast-track their gold project into production. The project is the 100%-owned Mount Hamilton property located at the southern end of the prolific Battle Mountain Trend in Nevada. ... The company’s plan is to put the Centennial Gold Deposit through the mine permitting process as quickly as possible while advancing numerous other targets at the same time. Located in the central portion of the property, the Centennial area was extensively explored by Philips Petroleum Corporation between 1960 and 1980. Work by Philips resulted in historical mineralized resources in a gold-silver zone as well as a tungsten-molybdenum-copper zone that is mostly on the flanks and below the gold zone. ... There is no exploration downside to this story. The future of the company rests on the management’s ability and knowledge of the permitting process. Fortunately, Ely is run by experienced professionals that have already been involved with bringing mines into production in the past. Buy Ely Gold and Minerals up to \$0.30.”

Luke Burgess, Hard Money Millionaire, [www.angelpub.com](http://www.angelpub.com), 877-528-2645, 6/11/10

“**Titanium Metals Corp.** (TIE 20.52 NYSE) was a Cabot Top Ten Report favorite back in 2004, 2005 and 2006, when this light, durable metal was in demand for all kinds of high tech, automotive and aerospace applications. The Great Recession forced lots of businesses to dial back their buying, which, while it never produced an actual quarterly loss for the company, certainly took a bite out of both revenues and earnings. Now, partly as a result of a recovering economy and partly because airplanes and other big titanium products just wear out and need replacing, investors are betting that the time has come for a renewal of demand that will drive earnings again. Titanium is vital to many industries, including chemicals (where titanium valves and piping resist corrosion), oil and gas, and aerospace, among others. Boeing is going into heavy production of its long awaited DreamLiner, and Boeing contributed 12% of 2008 revenues. It’s a simple, strong story.

### Technical Analysis

“TIE built a pretty base beginning in late March. The stock traded sideways under resistance at 17, then swung lower as market volatility increased. After correcting to as low as 14 in May, the stock leapt to 20 in two quick week-long rallies, and is now testing the waters above 20, which marks its highest price since May 2008. TIE isn’t cheap, but this is a good looking breakout on good volume. A correction of at least a point and a half or so should appear pretty soon, and that’s when to get in. A pullback is possible and even likely, but we see strong support just above 18. Suggested Buy Range: 18.5-21”

Michael Cintolo, Cabot Top Ten Report, [www.cabot.net](http://www.cabot.net), 978-745-5532, 6/14/10

“**SanDisk Corp.** (SNDK 48.70 Nasdaq) is a top producer of flash memory data storage devices. The company’s best-selling products are removable and embedded memory cards that are used in a wide variety of electronic gadgets, including: digital cameras, medical devices, networking equipment and notebook computers. SanDisk’s business customers include: Canon, Eastman Kodak, Ericsson, Panasonic and Siemens. The company also sells its products directly to consumers through retailers like Best Buy and Office Depot. The company’s latest high-tech device is the solid-state disk drive, a hard drive that has no moving parts and, therefore, makes electronics operate more efficiently. I recently bought a new Apple MacBook Pro (you know how much I love Apple) with a 128-gigabyte solid-state disk drive, and I can already tell how much the new drive is boosting my laptop’s performance. SanDisk also makes flash memory for the incredibly popular iPad tablet, so, with the help of Apple, the company should post huge second-quarter sales and

earnings. In the first quarter, the company’s sales rose 65.3% to \$1.09 billion, up from \$659.5 million in the same quarter a year ago. During the same year-long period, SanDisk’s earnings surged to \$234.7 million, or \$0.99 per share, compared with a loss of \$208 million, or \$0.92 per share, last year. The analyst community had expected earnings of \$0.59 per share on sales of \$986 million so the company actually posted a 67.8% earnings surprise and a 10.5% sales surprise! For the second quarter, the analyst community is expecting 55.8% sales growth and 138.9% earnings growth. Gartner Inc., a technology research group, recently revised its 2010 forecast for worldwide chip sales substantially higher to \$290 billion. This is a 27.1% increase from 2009’s total chip sales of \$228 billion. This is great news for SanDisk and another reason why the stock is our New Buy for this month.”

Louis Navellier, Blue Chip Growth Letter, [www.bluechipgrowth.com](http://www.bluechipgrowth.com), 800-718-8289, 6/14/10

“Some 30 years after the dawn of the biotech industry, several biologic medicines—drugs that are produced not chemically but organically, in living material such as yeast or animal cells—are scheduled to come off patent protection, which means that they will face competition from generic drug makers. [But because] biologics are organically based, they can’t be chemically analyzed. The only way to check to see whether the drug is safe and effective is to clinically test it. In fact, new legislation ... requires biosimilar manufacturers to do exactly that. ... This makes biosimilars a lot more expensive to make than standard generic drugs. ... The company set to see the greatest benefit from biosimilars is one of the world’s leading generic manufacturers and one of the industry’s best performers. The best part is that Israel-based **Teva Pharmaceutical Industries** (TEVA 53.62 Nasdaq) is not only poised to see billions in new sales from biosimilars, it’s also very attractively priced. Teva, with a market cap of \$47.9 billion and 2009 annual sales of \$13.9 billion, makes hundreds of non-branded drugs including dozens of recognizable names. ... Nevertheless, the shares are trading at only 20 times trailing earnings and only about 12 times estimates. The consensus forecast for Teva’s 2010 results is \$4.53. Even at its current valuation, that implies a fair value of \$90.60, a 64% increase from today’s price. ... The reason Teva will benefit from the biosimilar revolution is simple: Cash. Teva has plenty of it and others don’t. It consistently keeps \$2 billion on hand, funds that can be deployed to begin production of and gain approval for biosimilars. ... I’m adding shares of Teva to the Government-Driven Investing portfolio ... with a \$90 price target.”

Andy Obermueller, Government-Driven Investing, [www.streetauthority.com](http://www.streetauthority.com), 301-216-2005, 6/1/10

*Projected price trends in the energy sector inspired a number of oil- and gas-related stock recommendations this month. Chris Vermeulen, of TheGoldAndOilGuy, discusses these trends:*

*“Crude oil has been trending down for a couple months and recently rebounded to test its resistance level. It looks as though oil is forming a bear flag which generally means we should see lower prices in the near future. But another \$1-2 move up could trigger a surge of buyers if this resistance level is broken which is why this week should be volatile... it’s a 50/50 chance for commodities to either rally or sell off.” –Chris Vermeulen, TheGoldAndOilGuy, [www.thegoldandoilguy.com](http://www.thegoldandoilguy.com), 705-888-2384, 6/13/10*



**“CARBO Ceramics, Inc.** (CRR 76.52 NYSE), a company that we’ve had our eye on for weeks, isn’t your typical [energy resource] play. They’re not a driller, and they don’t directly own some piece of land with billions of barrels of oil, or even trillions of cubic feet of natural gas. However, what they do offer is a chance to have a hand in shale wells across the world. Carbo is the world’s largest supplier of ceramic proppant. What is a proppant, and why is it so important for horizontal drillers? During the hydraulic fracturing process, fluids are pumped down a well at high pressures. The goal is to create fractures in the rock formation, allowing oil and gas to flow more freely. In the past, companies would use sand as a proppant. Carbo came along and changed the game forever. By using ceramic proppant over the alternatives, companies can increase their estimated ultimate recovery by 30%. ... We strongly recommend you pick up shares of Carbo Ceramics at current prices.”

Brian Hicks, Ian Cooper & Keith Kohl, *The \$20 Trillion Report*, [www.angelpub.com](http://www.angelpub.com), 877-528-2645, 6/3/10

**“Nabors Industries Ltd.** (NBR 21.61 NYSE) is the largest on-shore resource-drilling contractor in the world. They are the dominant drilling company in the USA and in North America, but also have major operations in most regions of the world. They have annual sales of about \$5 billion and a market capitalization of about \$8 billion. Net profit in recent years has been about \$1 billion. The return on shareholders’ equity has been in the 7% to 30% range for the past ten years. ... Although we agree that additional land drilling of oil wells in the United States has passed the peak, we do believe that other energy and mineral drilling efforts have major growth ahead. To replace oil in our economy over the next decade, we will need coal, natural gas, nuclear, and geothermal power in large amounts. Nabors is likely to be number one in the big three ‘boring’ industries. These are (1) mineral exploration (coal, shale, uranium, gold, silver); (2) geothermal power (hundreds of potential sites); (3) natural gas (thousands of sites in proven fields). In addition, the rest of the world still has lots of land-based oil drilling opportunities and Nabors may expand into other areas. ... Our short-term target price for the stock in the next year is \$30 per share. Our two-to-three year target is \$48 per share. We believe that the timing for

this stock will improve in the near future. This is a large-cap stock with moderate risk. It is currently somewhat out of favor because many investors and analysts view the price of natural gas as cyclical and too low. It does not pay a cash dividend, even with annual cash flow of about one billion dollars. This should be a core holding in any portfolio that seeks to profit from the apparent long term shortage of energy and the advance of natural gas and alternative energy sources.”

Larry Lindquist and Robert E. Lepic, *Lindquist/Lepic Market Letter*, 3011 S. Josephine St., Denver, CO 80210, 800-743-9346, 6/10

“On the energy front, oil looks to move higher as we move into June. ... One of my favorite oil & gas stocks is **Occidental Petroleum Corp.** (OXY 86.80 NYSE). I personally own this stock and plan on buying more of it this week. The fundamentals are strong for this stock, as reflected in my fundamental score of 60 out of 100. ... The growth rate for total sales for the most recent quarter versus the same quarter a year ago comes in at 54.5%, compared with 14.3% for its industry (oil and gas operations), and an average growth rate of 13.3% for the S&P 500. The growth rate in sales during the past five years for OXY is 7.1%. ... OXY’s price-to-earnings ratio (P/E) of 18.5 makes it somewhat overvalued compared with its peers. In early May OXY announced a 15% increase in its annual dividend to \$1.52 per share, making for a yield of 1.8% based on Friday’s closing price. OXY has paid quarterly dividends for the last 35 years, and has raised the dividend every year since 2002. My technical score on OXY is a paltry 10 out of 100. OXY is still below my trendline and is not giving a new technical ‘buy.’ The safer play would be to wait until OXY is trading back above the \$84.50 level, which should confirm a ‘buy’ signal trend. However, remember that our window of opportunity for OXY is just about three weeks, if the time-cycle forecasts are accurate. As such, I am buying now even though it could be risky. ... Target price = \$95.00, Potential Profit = +16.5%.”

*Editor’s Note: OXY pulled above 85 as the overall market strengthened on Monday June 14, confirming Turner’s predicted buy signal trend.*

Mike Turner, *Mastering the Markets*, [www.streetauthority.com](http://www.streetauthority.com), 301-216-2005, 5/31/10

“**NIVS IntelliMedia Technology Group, Inc.** (NIV 2.24 AMEX) is an integrated consumer electronics company that designs, manufactures, markets and sells intelligent audio and video products and mobile phone products in China, Greater Asia, Europe, and North America. The NIVS brand has received the ‘Most Popular Brand’ distinction in China’s acoustic industry for three consecutive years, among numerous other awards. NIVS has developed leading Chinese speech interactive technology, which forms a foundation for the Company’s intelligent audio and visual systems, including digital audio, LCD televisions, digital video broadcasting set-top boxes, peripherals and more. ... Since November, the Shanghai Index has fallen 25%. This caused most Chinese sector stocks to drop too. Knowing that situations like this cause good stocks to fall to undervalued prices, we’ve been searching for a company that fits this criteria, and NIVS IntelliMedia does. In April, the Company completed a \$22 million financing at \$3.29. Since then the price has fallen to the \$2.21 level. Insiders own about 45% of the 40 million total shares outstanding, and institutions own about 2% of the float (shares in public hands). The Company has about \$30 million in cash and a book value just under \$2 per share. Debt is \$55 million. NIVS IntelliMedia has excellent growth in revenues and earnings. The negative factor is that the price is in a downward trend due to the falling Chinese market. NIVS IntelliMedia [reported] excellent first quarter financial results for the period ended March 31. Buy Recommendation”

Bill Mathews, *The Cheap Investor*, [www.thecheapinvestor.com](http://www.thecheapinvestor.com), 847-697-5666, 6/10

“**Lear Corp.** (LEA 70.30 NYSE) is a major global supplier to automobile manufacturers, producing seat systems and electrical power management systems. The company grew rapidly, making 18 acquisitions since becoming a public company in 1994. However, these acquisitions left Lear with a high level of debt, which caused the company to struggle when world-wide auto production began to decline sharply in 2007. Lear filed for Chapter 11 in July 2009, but it was able to emerge from bankruptcy only four months later. Lear actually began to reshape itself well before it filed for Chapter 11. Since 2005 it has closed 35 manufacturing and 10 administrative facilities, and cut its headcount by 35,000. Much of this restructuring focused on moving away from high-cost locations with the result that today half of Lear’s facilities and 75% of its workforce are based in low-cost countries. The Chapter 11 filing allowed the company to complete its restructuring by reshaping its balance sheet. When Lear emerged from Chapter 11, it had less than \$930 million in long-term

debt, compared to more than \$2.3 billion at the end of 2007. During the first quarter of 2010, the company was able to further refinance so that by early April it had only about \$745 million in debt at a low interest rate and with no maturities until 2018 and \$1.3 billion in cash. While automobile sales still have a long way to go to recover to historical levels, there are signs that a turnaround is underway globally. In the first quarter of 2010, worldwide automobile production was up 47% over the prior year. Lear has a large backlog of business, and recently boosted its guidance for 2010 results. As Lear returns to profitability, shareholders could gain in several different ways. As investors become more comfortable with the rebound in the automotive sector, they will value Lear’s stock more highly. Secondly, with strong cash flow, Lear could reinstitute a dividend. Also, as the automotive supply business continues to consolidate, Lear could be either an acquirer or an acquisition target. We recommend buying Lear up to 90.”

George Putnam, III, *The Turnaround Letter*, [www.turnaroundletter.com](http://www.turnaroundletter.com), 617-573-9550, 6/10

“**Leucadia National Corp.** (LUK 21.78 NYSE) essentially is two very shrewd businessmen, Ian Cumming and Joseph Steinberg, who understand how to make money from assets whose value others don’t see or understand. ... Leucadia holds an eclectic accumulation of businesses, some of which LUK operates and others in which it is a passive investor. Historically, Leucadia’s best known investments have been in finance and telecommunication, beaten-down companies, some acquired out of bankruptcy, which they turned around and stoically waited for a buyer to take them off their hands at a premium. Lately, Wall Street sees Leucadia as a natural resources company, which might not jibe with LUK’s past but is justified, since Cumming and Steinberg over the last few years have made significant investments in mining and other natural resource-related assets. During the latest market downdraft as investors grew concerned that global economic recovery would be tepid or even non-existent (deflation anyone?), everything from oil to iron dropped faster and further than the rest of the market. Since we continue to believe that the economic recovery will continue, although perhaps in fits and starts, ‘stuff stocks’ have a bright future not only because their products are essential for global economic growth but also because as hard assets, they are likely to retain value should the dollar again falter and/or inflation return. Since they peaked in mid-April at \$28.05, shares in Leucadia are now at \$20.41, a 27% drop but still nearly twice the price they fell to at the March 2009 bottom. ... Historical comparisons

## VALUE STOCKS

show [that] LUK's current Price to Earnings ratio is less than a quarter of where it's been over the last decade, Price to Sales is at two-thirds and Price to Book is three-quarters, all of which either are or are close to their lows of the past decade. We recommend buying LUK up to \$27."

Gray Cardiff, Sound Advice, [www.soundadvice-newsletter.com](http://www.soundadvice-newsletter.com), 800-825-7007, 6/11/10

**"The Hain Celestial Group, Inc.** (HAIN 22.83 Nasdaq) has 43 brands of organic, natural and specialty foods, from organic bread maker Arrowhead Mills to infant food line Earth's Best to Avalon Organics shampoo and personal care products. ... In its latest quarter, the third quarter ended March 31, Hain's sales were \$222 million (including a \$24 million write-down of inventory and elimination of its fresh sandwich service to Marks & Spencer) compared to \$234 million the year prior. The write-down overshadows the fact that gross margins improved and that top-line growth shows a lot of promise. Hain also continues to expand its reach, swapping an interest in Kosher Valley foods for a stake

in well-regarded kosher poultry provider Empire Foods, and agreeing to acquire World Gourmet Marketing, which makes 'Sensible Portions' branded products. ... In May, Carl Icahn announced he had acquired an 11.9% stake in the company, proclaiming the firm undervalued and saying founder [Irwin] Simon was on board with the goal of maximizing the company's shareholder value. ... Some of Icahn's thinking likely focuses on the fact that even as organic foods have maintained themselves through the recession, sales are bound to improve as the economy perks up and consumers feel freer with their spending, especially in the U.S., where Hain generates about 81% of its sales. The recession showed that Hain has a good core of true believers who buy organic no matter what, while a rebound will bring in the marginal customer who is willing to return to the 10% to 15% premium Hain charges for its products. ... Support looks good at 20 and then 19, while resistance may come in closer to 23 and then in greater force if shares attack 30. Cabot recommendation: WATCH"

Brendan Coffey, Cabot Green Investor, [www.cabot.net](http://www.cabot.net), 978-745-5532, 6/10/10

## OPTIONS

"We have one recommendation for you this week. It is based on what we are seeing in the overall market and the bullish signal for the overall market from the Cabot Options Trader Market Barometer. With the S&P moving back above the 52-week moving average and support holding at the 1,045-level, we think the S&P is poised to move back up to the 1,150-level. As a result, we are recommending calls on the **SPDR S&P 500 ETF** (SPY 111.94 NYSE) with a target of 115 for the underlying ETF. Recommendation: Buy the July 109 Call on the S&P 500 Spyderys. The current bid price is 3.98 and the ask price is 4.00. We recommend not paying more than 4.30 for this option."

Rick Pendergraft, Cabot Options Trader, [www.cabot.net](http://www.cabot.net), 978-745-5532, 6/14/10

**"ArvinMeritor, Inc.** (ARM 15.77 NYSE) has added 33% in 2010, driven steadily higher along the support of its 10-week and 20-week moving averages. In fact, in the last 60 sessions, ARM has outperformed the SPX by 21 percentage points. The equity recently pulled back to the support of these intermediate-term trendlines, which have ushered the shares higher since May 2009, suggesting the stock is about to embark on the next leg of its uptrend. However, some traders remain skeptical, evidenced by the stock's 10-day International


Securities Exchange (ISE) and Chicago Board Options Exchange (CBOE) put/call volume of 0.75, which ranks in the 69th percentile of its annual range. Plus, 18.8% of the stock's total available float remains tied up in short interest. Should the stock once again bounce off trendline support, the bears could get spooked, sparking a short-covering rally to push the shares even higher. Recommendation: Buy the August 21, 2010 10-strike call. Maximum Entry Price is 5.80. [Recent bid/ask was 5.20/5.50.]"

Bernard G. Schaeffer, Option Advisor, [www.schaeffersresearch.com](http://www.schaeffersresearch.com), 800-448-2080, 6/10

"Options trading has begun on the Barclay's ETNs that mimic short-term and intermediate-term volatility—the **iPath S&P 500 VIX Short Term Futures ETN** (VXX 26.72 NYSE) and the **iPath S&P 500 VIX Mid-Term Futures ETN** (VXZ 85.24 NYSE). Trading started on May 28th. The options are being traded on all of the listed option exchanges—thereby breaking CBOE's stranglehold on listed volatility options. ... Certain strategies will now be available to traders that have not been available with \$VIX options—the 'standard' calendar spread, for example."

Lawrence G. McMillan, The Option Strategist, [www.optionstrategist.com](http://www.optionstrategist.com), 800-724-1817, 6/3/10

“The National Oceanic and Atmospheric Administration called for an ‘active or extremely active’ hurricane season expected for the Atlantic Basin this year. ... After the one-two punch of Katrina and Rita back in 2005, natural gas went from \$10 to \$14.75 mmbtu. However, the price of oil actually dropped. This is because oil is fungible and natural gas isn’t; natural gas is moved in pipes locally and it has local prices. Furthermore, the price of natural gas has fallen through the floor, due to the twin apocalypse of falling demand based on the recession and massive new supply based on new fracturing techniques. This is my favorite type of chart. I call it an ‘L’ chart. The [natural gas] ETF has fallen so much that the only people left in are the strong hands of long-



term holders. Everyone who was going to sell has sold. Furthermore ... the price of natural gas has broken out above \$4.40. The MACD crossed over mid-month and volume is increasing. That is a clear sign of a bottom with good support around \$4.48—or about \$7.60 on the **United States Natural Gas Fund, LP** (UNG 8.84 NYSE). You can buy the UNG itself, or if you are feeling more adventurous, I recommend buying the October 2010 \$10 strike price options. They are currently being traded at \$0.34 (Symbol: UNG101016C00010000).”

Christian DeHaemer, Crisis & Opportunity, [www.angelpub.com](http://www.angelpub.com), 877-528-2645, 6/11/10

### Second Opinion: United States Natural Gas Fund

“UNG was as high as 63 at the height of its popularity in August, 2008. It then plunged 89% over the next 18 months to a low of 7 by late April. It has now triggered a buy signal on intermediate-term technical indicators. ... We also like UNG because it often moves independent of the stock market, a plus in these uncertain times for the stock market. We have an upside target of 16, and suggest a trailing mental protective stop at 6.50.”

Sy Harding, Long and Short Stock Advisor, [www.longandshortstockadvisor.com](http://www.longandshortstockadvisor.com), 386-943-8014, 6/9/10

“The **Caldwell & Orkin Market Opportunity Fund** (COAGX) is not afraid to stand out. A long/short open-end mutual fund actively managed by Michael B. Orkin et al., the fund offers superior risk-adjusted returns with low volatility (slightly more than an intermediate bond fund) and very little correlation to major market indices and/or other asset classes and/or investments. ... The fund achieves its superior risk-adjusted returns not only through its proprietary stock selection process, but by investing in both long and short positions in predominantly individual equities. ... The team uses quantitative models for deciding when to enter the market and which sector to go long or short. ... Overall, the Caldwell & Orkin Market Opportunity Fund has proven to be a great diversification vehicle in short, intermediate and long term periods. The management team has proven time and again that their experience results in their low volatility and non-correlation. ... They may not always be on the mark with their decisions to go long or short, but over the long-term due to their non-correlation and resulting portfolio reward-to-risk enhancement improvements, low volatility and major loss prevention attributes, the fund has been a strong performer and a key component of constructing Lower Volatility Portfolios since the inception of this style of investing.”

Louis P. Stanasolovich, CFP, Risk-Controlled Investing, [www.legend-financial.com](http://www.legend-financial.com), 412-635-9210, 4/10

“The biggest opportunity for energy investors today is natural gas. ... The **First Trust ISE-Revere Natural Gas** (FCG 18.08 NYSE) ETF is a basket of 30 North American stocks that are in the business of exploring for oil and natural gas. ... Year-to-date the fund is down 6%, but over the last year it gained 14.8%. ... For investors who believe that the prices of oil and natural gas are heading higher, this ETF is a good way to get exposure without the risks associated with a single stock. ... Buy below \$19.”

Ian Wyatt, Ian Wyatt's \$100k Portfolio, [www.100kportfolio.com](http://www.100kportfolio.com), 866-447-8625, 6/14/10

“**PowerShares DB Agriculture Fund** (DBA 24.04 NYSE)—While it is still far too early to declare that a bottom has been put in for shares of this ETF, the manner in which the price spiked down earlier this month in a single day—and then slowly recouped all of the loss in a steady string of up days—at least creates the possibility the worst may be behind us now. ... If you haven’t yet, buy a bit to make sure you’ve got some skin in the game. DBA remains a buy under \$26.”

Nate Pile, Nate's Notes, [www.notwallstreet.com](http://www.notwallstreet.com), 707-433-7903, 6/11/10

*Last recommended in Dick Davis Digest issue 652 dated August 10, 2009, at \$15.23 by US Investment Report. Previously recommended in Dick Davis Digest issue 640 dated February 9, 2009, at \$11.37 by Stellar Stock Alert.*

“Shares of **EMC Corp.** (EMC 19.11 NYSE) struggled with the market sell-off but showed some decent strength toward the end of May. While dropping with the market, EMC brushed through its 200-day moving average and its long-term uptrend line. The support bent, but it didn’t break, as the stock was able to rebound. As the month ended, the stock was threatening to move back above its 50-day moving average, which never had a chance to turn south. If it can push back above the shorter-term average, it will be almost as if the downturn never happened. The uptrend remains solidly in place. And EMC remains a strong buy up to \$20.”

Richard Schmidt, Stellar Stock Alert, [www.stellarstockalert.com](http://www.stellarstockalert.com), 800-456-5705, 6/10

*Last recommended in Dick Davis Digest issue 669 dated April 21, 2010, at \$2.77 by SmallCapInvestor PRO.*

“Recent addition **Joe’s Jeans, Inc.** (JOEZ 2.30 Nasdaq) was a strong performer last week. The stock rose nearly 5%, bucking the broader market trend. There was no specific news announcement that we can credit as a catalyst for the stock’s performance. But I suspect that investors realize the recent sell-off in shares was overdone, and hedge funds and the like are starting to accumulate shares once again.”

Ian Wyatt, SmallCapInvestor PRO, [www.smallcapinvestor.com](http://www.smallcapinvestor.com), 866-447-8625, 6/8/10

*DGP was last recommended in Dick Davis Digest issue 671 dated May 19, 2010, at \$32.54 by The National Investor. TBT was last recommended in issue 672 dated June 2, 2010, at \$39.66 by The National Investor.*

“**PowerShares DB Gold Double Long ETN** (DGP 33.18 NYSE) remains an ‘Accumulate.’ Unlike so many Johnny-come-latelys who couldn’t spell gold until recently, I am not at all concerned about gold’s inability the last few days to add meaningfully to its slight new nominal high. At the moment, about the only thing that does concern me about gold is the possibility (a 1 in 3 chance right now) that the euro does get back above its previous support, and keeps moving. Forget the U.S. dollar—gold’s moves will remain most closely tied to the euro’s fortunes. If the euro gets a head of steam and the shorts get

scared and start to run for the hills, we’ll have to think about exiting DGP and, perhaps, trading back into the ProShares UltraShort Gold ETF (NYSE: GLL).

“Last but not least, SELL the **ProShares UltraShort 20+ Year Treasury ETF** (TBT 39.62 NYSE). ... As you’ve noticed, the stock market’s sharp rallies—even though they haven’t lasted long—have not been accompanied by the kind of commensurate move higher in yields you’d expect to see if 1) the rally was legitimate and 2) fear was less. Frankly, the upside here is much more limited than in many other things we could be in if stocks rallied sharply and sustainably. It’s not worth tying up 5% of a portfolio in; so get out while we’re still a little ahead of the game.”

Chris Temple, The National Investor, [www.nationalinvestor.com](http://www.nationalinvestor.com), 715-939-1200, 6/10/10

*Last recommended in Dick Davis Digest issue 654 dated September 7, 2009, at \$51.10 by Cabot Stock of the Month Report.*

“**Salesforce.com** (CRM 95.12 NYSE), originally recommended by Cabot Top Ten Report, is a potential leader of the next advance. The stock actually moved out to new all-time highs last week before being yanked back down by the market. Still, as the hands-down leader in cloud computing, we think the stock has a great chance to be a leader of the next advance. HOLD.”

Timothy Lutts, Cabot Stock of the Month Report, [www.cabot.net](http://www.cabot.net), 978-745-5532, 6/8/10

*Last recommended in Dick Davis Digest issue 669 dated April 21, 2010, at \$26.12 by Cabot Green Investor.*

“**Rubicon Technology, Inc.** (RBCN 31.76 Nasdaq)—The MOCVD maker (used to make LEDs, photovoltaics) has found support at its 50-day moving average. Featured in our April 2010 issue, it was sold early last month in defensive measure. The fact it has held up while other LED leader stocks have faltered in recent weeks makes it intriguing. Right now, however, shares are still testing the 50-day line and show signs of institutional selling, so it’s best kept on watch for the next few sessions to ascertain if Rubicon is just late to the LED-related selling sector wide. News wise, the company has been quiet, but it did cancel a plan to sell \$100 million in a mix of equities, warrants and debt, a sign the market environment is less than embracing of additional liquidity right now. WATCH.”

Brendan Coffey, Cabot Green Investor, [www.cabot.net](http://www.cabot.net), 978-745-5532, 6/10/10

## IN THIS ISSUE

Company Name (Symbol)	Page	Product/ Service	52-week Low-High	EPS Est. EPS Est.* Indicated**						Company Phone Numbers
				Recent Price	P/E Ratio	(current yr.)	(next yr.)	Annual Dividend	Yield	
Activision Blizzard Inc (ATVI)	4	Technology	9.93 - 13.01	11.31	15	0.08	0.74	0.15	1.30%	310-255-2000
ArvinMeritor Inc (ARM)	9	Consumer Cyclical	2.90 - 17.22	15.77	48	0.54	1.86	n/a	n/a	248-435-1000
CARBO Ceramics Inc (CRR)	7	Energy	31.52 - 78.98	76.52	26	2.84	3.56	0.72	0.90%	281-921-6400
Cummins Inc (CMI)	4	Capital Equipment	30.55 - 76.95	75.25	19	3.73	5.32	0.70	0.90%	812-377-5000
Dr Reddys Labs Ltd (RDY)	3	Health Care	14.03 - 33.14	31.08	22	1.04	1.38	0.11	0.40%	91-40-2373-1946
Ely Gold & Minerals, Inc. (ELY.V)	5	Industrial Materials	0.08 - 0.66	0.24	n/a	n/a	n/a	n/a	n/a	604-488-1104
EMC Corp (EMC)	11	Technology	12.31 - 20.00	19.11	15	1.20	1.36	n/a	n/a	508-435-1000
Express Scripts Inc (ESRX)	5	Health Care	30.33 - 53.72	53.26	21	2.49	3.27	n/a	n/a	314-996-0900
interCLICK Inc (ICLK)	4	Capital Equipment	2.00 - 6.00	3.92	56	0.07	0.13	n/a	n/a	646-722-6260
Janus Capital Grp Inc (JNS)	5	Financial	9.37 - 16.06	10.44	15	0.70	0.85	0.04	0.40%	303-333-3863
Joes Jeans Inc (JOEZ)	11	Consumer Cyclical	0.60 - 3.60	2.30	33	0.07	0.13	n/a	n/a	323-837-3700
Lear Corporation (LEA)	8	Consumer Cyclical	0.34 - 84.97	70.30	18	3.76	6.61	n/a	n/a	248-447-1500
Leucadia Natl Corp (LUK)	8	Capital Equipment	18.00 - 28.37	21.78	n/a	n/a	n/a	n/a	n/a	212-460-1900
Nabors Industries Ltd (NBR)	7	Energy	13.78 - 27.05	21.61	20	1.03	1.64	n/a	n/a	441-292-1510
NIVS IntelliMedia Tech Gp (NIVS)	8	Consumer Goods	2.03 - 4.38	2.24	3	n/a	n/a	n/a	n/a	86-75-2312-5862
Occidental Petroleum Corp (OXY)	7	Energy	58.67 - 90.99	86.80	14	5.85	7.64	1.52	1.80%	310-208-8800
Rubicon Technology Inc (RBCN)	11	Technology	8.70 - 32.15	31.76	54	0.56	1.09	n/a	n/a	847-295-7000
Salesforce.com Inc (CRM)	11	Technology	35.27 - 97.09	95.12	81	1.16	1.53	n/a	n/a	415-901-7000
SanDisk Corp (SNDK)	6	Technology	13.02 - 48.92	48.70	13	3.71	3.54	n/a	n/a	408-801-1000
Starbucks Corp (SBUX)	4	Retail	12.76 - 27.94	27.87	22	1.26	1.45	0.40	1.40%	206-447-1575
T-3 Energy Services (TTES)	5	Energy	10.89 - 32.13	31.98	26	1.20	2.13	n/a	n/a	713-996-4110
Teva Pharmaceutical (TEVA)	6	Health Care	46.14 - 64.95	53.62	12	4.54	5.12	0.58	1.10%	972-3926-7267
The Hain Celestial Group (HAIN)	9	Consumer Staple	14.45 - 23.56	22.83	19	1.10	1.31	n/a	n/a	631-730-2200
Titanium Metals Corp (TIE)	6	Basic Material	7.34 - 20.77	20.52	51	0.39	0.62	n/a	n/a	972-233-1700

ETF Name (Symbol)	Page	52-week Low-High	Recent Price	Indicated** Annual Dividend	Yield	Company Phone Numbers
First Tr ISE-Rev Nat Gas (FCG)	10	11.02 - 19.41	18.08	0.05	0.30%	630-765-8000
iPath S&P 500 VIX M Etn (VXZ)	9	65.15 - 104.32	85.24	n/a	n/a	877-764-7284
iPath S&P 500 VIX S Etn (VXX)	9	17.84 - 80.27	26.72	n/a	n/a	877-764-7284
Powershrs DB Agricultre (DBA)	10	22.85 - 27.20	24.04	n/a	n/a	800-983-0903
Powershrs DB Gold Dbl Etn (DGP)	11	18.66 - 34.10	33.18	n/a	n/a	800-983-0903
Proshrs Ultshst 20+ Yr Trsy (TBT)	11	37.55 - 56.21	39.62	n/a	n/a	866-776-5125
SPDR S&P 500 (SPY)	9	87.00 - 122.12	111.94	2.10	1.90%	212-306-1844
United States Nat Gas (UNG)	10	6.72 - 16.26	8.84	n/a	n/a	510-522-3336

Mutual Fund Name (Symbol)	Page	Fund Objective	NAV	3 mos.	Return (%) 1-year	3-year	Min. Invest.	Company Phone Numbers
Caldwell & Orkin Mkt Opp (COAGX)	10	Long-Short	19.44	(1.14)	(12.60)	4.40	\$25,000	800-467-7903

Prices are as of June 15, 2010. Estimates for Canadian stocks are in Canadian dollars.

\*Using forward estimates. When available, the average estimate across all Wall Street analysts. Failing that, we've quoted the excerpted editor's own estimate, if it is available.

\*\*Indicated Annual Dividend and Yield may vary as a result of price changes.

Dick Davis Digest presents news, information, opinions and recommendations of individuals or organizations whose views are deemed of interest. It should not be assumed that such recommendations, past or future, will be profitable or will equal past performance. The Dick Davis Digest does not itself give investment advice, act as investment advisor or advocate the purchase or sale of any security or investment. All contents are derived from data believed reliable, but accuracy cannot be guaranteed. Excerpted material represents only part of the total information or viewpoint found in the original source and should not necessarily be relied on as a sole source of information and opinion for making investment decisions. The Dick Davis Digest is published by Cabot Heritage Corp. Officers, directors and employees of Cabot Heritage Corp. may own securities of the companies reported on in Dick Davis Digest. All rights reserved. ©Cabot Heritage Corp. 2010. Reproduction of this publication in whole or in part is strictly forbidden.